Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S4JL
|
|||
| Former ID |
DIB015319
|
|||
| Drug Name |
Simtuzumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1], [2] | |
| Primary sclerosing cholangitis [ICD-11: DB96.2; ICD-10: K83.0] | Phase 2 | [3] | ||
| Company |
Gilead sciences
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8412). | |||
| REF 2 | ClinicalTrials.gov (NCT01769196) A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.